Nuvation Bio Inc.
NUVB
Updated: 23/09/2026, 07:04:26
Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a poly ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.
No summaries found.
- Share price
- $6.10
- Market cap
- $2.12B
- Exchange
- NYSE
- Currency
- USD
- CEO
- David T. Hung
- Employees
- 305
- IPO date
- 26/08/2020
- Beta
- 1.526
- Last dividend
- $0.00
- Day range
- $5.95 – $6.14
- 52-week range
- $2.99 – $9.75
- 1-day performance
- 0.49%
- 1-year performance
- 104.01%
- Current drawdown (1Y)
- -37.44%
- CIK
- 0001811063
- CUSIP
- 67080N101
- ISIN
- US67080N1019
- Created
- 07/12/2025, 05:31:48
- Last update
- 23/09/2026, 07:04:26
Track Nuvation Bio Inc. with an AI analyst
See which prediction-market events move NUVB, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Nuvation Bio: Buy The Ibtrozi Launch (Rating Upgrade)
Seeking Alpha • STOCK • 08/06/2026, 10:15:49
Nuvation Bio Inc. (NUVB) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 25/05/2026, 09:17:30
Nuvation Bio Inc. (NUVB) Presents at H.C. Wainwright 4th Annual BioConnect Investor Conference Transcript
Seeking Alpha • STOCK • 22/05/2026, 23:00:43
Nuvation Bio Inc. (NUVB) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 13/05/2026, 14:40:56
Nuvation Bio Inc. (NUVB) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 04/05/2026, 23:33:25
Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update
PRNewsWire • STOCK • 04/05/2026, 18:10:00
Nuvation Bio Inc. (NUVB) Reports Next Week: Wall Street Expects Earnings Growth
Zacks Investment Research • STOCK • 27/04/2026, 13:05:41
Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026
PRNewsWire • STOCK • 21/04/2026, 20:00:00
Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026
PRNewsWire • STOCK • 20/04/2026, 18:05:00
Insider Sells 200K Shares of Biotech Company Nuvation Bio (NUVB)
The Motley Fool • STOCK • 13/04/2026, 02:04:41
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm
PRNewsWire • STOCK • 02/04/2026, 15:19:00
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB
GlobeNewsWire • STOCK • 24/03/2026, 18:13:00